Patients on Ozempic, Wegovy, and other GLP-1 receptor agonist medications are showing up in dermatologists' offices with something their prescribing physicians may not have anticipated: dramatically improved skin.
A Medscape report published July 9, 2026 synthesized emerging clinical observations and new genetic research suggesting that GLP-1 drugs may offer significant benefits for two of the most difficult-to-treat chronic inflammatory skin diseases — psoriasis and hidradenitis suppurativa (HS). One dermatologist profiled in the report described seeing patients with psoriasis experience nearly complete skin clearance on GLP-1 therapy alone.
